Economic Evaluation of an Integrated Care Program Compared to Conventional Care for Patients With Chronic Kidney Disease in Rural Communities of Thailand.
泰國農村社區慢性腎病患者綜合照護計畫與傳統照護的經濟評估。
Kidney Int Rep 2024-08-19
Projecting the potential cost-effectiveness of dapagliflozin for chronic kidney disease in Kuwait.
在科威特,dapagliflozin 用於慢性腎臟疾病的潛在成本效益。
J Med Econ 2023-02-16
Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysis.
將達帕格醇在慢性腎臟病中降低醫療資源利用和成本的效力轉化為醫療保健成本抵銷分析。
J Med Econ 2024-01-13
Mortality, Health Care Burden, and Treatment of CKD: A Multinational, Observational Study (OPTIMISE-CKD).
CKD的死亡率、醫療負擔和治療:一項跨國觀察性研究(OPTIMISE-CKD)。
Kidney360 2024-04-10
Cost-effectiveness of empagliflozin as add-on to standard of care for chronic kidney disease management in the United Kingdom.
在英國慢性腎臟病管理中 empagliflozin 作為標準治療的附加選項的成本效益。
J Med Econ 2024-05-17
Cost-effectiveness of add-on empagliflozin versus standard of care in management of CKD in Malaysia, Thailand and Vietnam - findings from a modelling study assessing an EMPA-KIDNEY eligible population, using CKD progression model.
在馬來西亞、泰國和越南管理慢性腎臟病中,添加 empagliflozin 與標準治療的成本效益比 - 來自一項模擬研究的發現,該研究評估了符合 EMPA-KIDNEY 資格的人群,並使用慢性腎臟病進展模型。
J Med Econ 2024-06-25
Benefits of dapagliflozin in chronic kidney disease for US commercial payers: A cost-offset analysis.
dapagliflozin 在美國商業保險支付者中對慢性腎病的益處:成本抵消分析。
J Manag Care Spec Pharm 2024-08-01
Navigating Choices in Nephrology: The Role of Patient-Reported Outcomes and Preferences in Economic Evaluations and Decisions in Health Care.
腎臟科中的選擇導航:病人報告的結果和偏好在健康照護經濟評估和決策中的角色。
Semin Nephrol 2024-09-03